Why BGPT?
logo

Author Claim Review

Examine the evidence base and provenance of specific claims made by authors or groups.Know what the science actually supports before you trust the answer.

Press Enter ↡ to review


     Quick Explanation



    Fen-Biao Gao is a world-class ALS/FTD neuroscientist (h-index 65, ~25,700 citations, 188 works) whose recent work on CYLD-driven FTD circuit dysfunction, C9ORF72 dipeptide-repeat translation, and progranulin lysosomal processing shows high novelty (scores 7-9) and solid rigor (7-8), with main blindspots being overexpression dependence and limited in vivo validation.


     Long Explanation



    Career Impact and Bibliometrics

    OpenAlex records 188 works with 25,676 citations and an h-index of 65 for Fen-Biao Gao (ORCID 0000-0001-8873-5404), with citations rising steeply after 2012 and peaking above 2,100/year (2020-2021), indicating sustained field-wide influence in neuroscience, cell biology, and genetics . His three most-cited works are co-authored autophagy guidelines (2012: 3,999; 2016: 5,894 citations), and landmark mechanistic papers include the C9ORF72 nucleocytoplasmic transport study in Nature (841 citations) and stress-granule interactome work in Cell (915 citations) . Career longevity is notable: first-author developmental work spans Drosophila dendritogenesis and oligodendrocyte timing since the 1990s .

    Recent Scientific Strength

    Three evaluated recent papers score 8 for scientific quality and 7-9 for novelty. The 2026 CYLD work links gain-of-function M719V-CYLD to bvFTD-like behaviors and mPFC layer-5 pyramidal neuron hypoexcitability via Akt-mTOR-autophagy dysregulation, with adequate per-condition electrophysiology sample sizes (n=12-19 cells/group) and both sexes included, though it relies on ~3-fold AAV overexpression and shows no TDP-43 pathology or neurodegeneration . The 2023 eLife paper maps canonical AUG initiation codons for antisense poly-PR/poly-PG translation in C9ORF72 ALS/FTD, showing EIF2D is dispensable for antisense DPR synthesis, but with only a few patient iPSC lines and overexpression plasmids . The 2017 cathepsin L work identifies the first lysosomal intracellular PGRN protease with detailed LC-MS/MS cleavage mapping, yet validation rests on overexpression systems and a single postmortem FTLD brain, with no Cat L knockout animal data . A 2016 EMBO Journal commentary on the C9ORF72-WDR41-SMCR8 RAB GEF complex reflects his group's leadership in defining C9ORF72's normal function .

    Critical Assessment

    Strengths: mechanistic depth across molecular, cellular, synaptic, circuit, and behavioral levels; multi-model approaches (mouse AAV, iPSC neurons, cell lines, Drosophila); consistent NIH funding (R37NS057553, R35NS097273, etc.); transparent limitation reporting and declared conflicts; leadership in defining central ALS/FTD mechanisms (C9ORF72 DPR translation, autophagy, progranulin lysosomal biology). Weaknesses/blindspots: recurring dependence on overexpression constructs across the CYLD, DPR, and cathepsin L papers, which may not recapitulate endogenous regulation; small patient-derived iPSC line numbers; limited in vivo validation (single postmortem brain in the cathepsin L study); translational gaps (absence of hallmark FTD pathology in the CYLD model). No evidence of fabricated data, undisclosed industry influence, or p-hacking was found in these records, though Biogen affiliations appear in one co-author list (declared). What would change this assessment: failure of independent labs to replicate the CYLD-M719V behavioral phenotype, or demonstration that cathepsin L does not process PGRN in intact brain, would materially weaken recent claims.



    Feedback:    

    Updated: October 30, 2026

     BGPT Author Review



    Scientific Quality

    90%

    h-index 65, ~25.7k citations, and co-authorship on field-defining Nature/Cell papers plus autophagy guidelines reflect elite scientific standing. Recent first/corresponding-author work is mechanistically deep and well-controlled. Main deductions: repeated reliance on overexpression systems and limited in vivo validation of key protease and start-codon claims; no detected data-integrity red flags.



    Communication Quality

    80%

    Papers are clearly structured with explicit problem statements, falsification criteria, methods detail, and software/tool reporting. Accessibility to non-specialists is moderate given dense cell/molecular terminology; recent work lacks notable lay summaries.



    Author Novelty

    80%

    Consistently high novelty scores (7-9): first identification of cathepsin L as a lysosomal PGRN protease, novel AUG-dependent antisense DPR translation mechanisms, and a first-in-field CYLD-M719V circuit-level FTD model. Not paradigm-breaking, but consistently first-mover on central ALS/FTD mechanisms.



    Scientific Rigor

    80%

    Adequate sample sizes for electrophysiology (n=12-19 cells/group), both sexes included, orthogonal methods (LC-MS/MS, electrophysiology, CRISPR, iPSC neurons), transparent limitation sections, and declared conflicts. Deductions: overexpression dependence across multiple papers, single-patient tissue validation, small iPSC line numbers, and limited in vivo rescue/causality experiments.

     Top Data Sources ExportMCP



     Hypothesis Graveyard



    CYLD-M719V causes FTD primarily through neuronal death: falsified in the model by absence of overt neurodegeneration or microgliosis at 12 months; dysfunction is functional, not degenerative.


    Antisense DPR translation is exclusively non-AUG/RAN-dependent: largely falsified by the eLife mapping showing canonical AUGs drive poly-PR and poly-PG.

     Science Art


    Author Review: Fen-Biao Gao Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT